Form 3

United States Securities and Exchange Commission
Washington, D.C. 20549

Initial Statement of Beneficial Ownership of Securities

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *
   Garner Denise
   (Last) (First) (Middle)
   1221 Broadway
   Oakland, CA 94612-1888

2. Date of Event Requiring Statement (MM/DD/YYYY)
   1/5/2015

3. Issuer Name and Ticker or Trading Symbol
   CLOROX CO /DE/ [CLX]

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
   ___ Director
   ___ 10% Owner
   X Officer (give title below)
   ___ Other (specify below)
   SVP - Chief Innovation Officer

5. If Amendment, Date Original Filed (MM/DD/YYYY)

6. Individual or Joint/Group Filing (Check Applicable Line)
   X Form filed by One Reporting Person
   ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

<table>
<thead>
<tr>
<th>Title of Security</th>
<th>Amount of Securities Beneficially Owned</th>
<th>Ownership Form: Direct (D) or Indirect (I)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common Stock</td>
<td>1083.0000</td>
<td>D</td>
</tr>
</tbody>
</table>

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

<table>
<thead>
<tr>
<th>Title of Derivative Security</th>
<th>Date Exercisable</th>
<th>Expiration Date</th>
<th>Title</th>
<th>Amount or Number of Shares</th>
<th>Conversion or Exercise Price of Derivative Security</th>
<th>Ownership Form of Derivative Security: Direct (D) or Indirect (I)</th>
<th>Nature of Indirect Beneficial Ownership (Instr. 5)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stock Option (Right to Buy)</td>
<td>9/14/2011</td>
<td>9/14/2020</td>
<td>Common Stock</td>
<td>1995.0000</td>
<td>$66.4800</td>
<td>D</td>
<td>Direct (D) or Indirect (I)</td>
</tr>
<tr>
<td>Stock Option (Right to Buy)</td>
<td>9/13/2012</td>
<td>9/13/2021</td>
<td>Common Stock</td>
<td>3060.0000</td>
<td>$68.1500</td>
<td>D</td>
<td>Direct (D) or Indirect (I)</td>
</tr>
<tr>
<td>Stock Option (Right to Buy)</td>
<td>9/11/2013</td>
<td>9/11/2022</td>
<td>Common Stock</td>
<td>8700.0000</td>
<td>$72.1100</td>
<td>D</td>
<td>Direct (D) or Indirect (I)</td>
</tr>
<tr>
<td>Stock Option (Right to Buy)</td>
<td>9/17/2014</td>
<td>9/17/2023</td>
<td>Common Stock</td>
<td>6730.0000</td>
<td>$84.4500</td>
<td>D</td>
<td>Direct (D) or Indirect (I)</td>
</tr>
<tr>
<td>Stock Option (Right to Buy)</td>
<td>9/17/2015</td>
<td>9/17/2024</td>
<td>Common Stock</td>
<td>7080.0000</td>
<td>$89.8200</td>
<td>D</td>
<td>Direct (D) or Indirect (I)</td>
</tr>
</tbody>
</table>

Explanation of Responses:
(1) Option vests in 4 equal installments - 1/4 on each of the first, second, third and fourth anniversaries of the grant date.

Remarks:
 garnerpoa.txt

Reporting Owners
<table>
<thead>
<tr>
<th>Reporting Owner Name / Address</th>
<th>Relationships</th>
</tr>
</thead>
<tbody>
<tr>
<td>GARNER DENISE</td>
<td>Director</td>
</tr>
<tr>
<td>1221 BROADWAY</td>
<td>10% Owner</td>
</tr>
<tr>
<td>OAKLAND, CA 94612-1888</td>
<td>Officer</td>
</tr>
<tr>
<td></td>
<td>SVP - Chief Innovation Officer</td>
</tr>
</tbody>
</table>

Signatures

By Angela Hilt, Attorney-in-Fact for 1/7/2015

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).


Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
January 5, 2015

Securities and Exchange Commission
450 Fifth Street N.W.
Washington, DC 20549

Ladies and Gentlemen:

This letter authorizes the following representatives of The Clorox Company, acting singly, to execute and file with you on my behalf future Forms 3, 4 and 5 respecting my holdings of equity securities of The Clorox Company:

Laura Stein, Senior Vice President, General Counsel
Angela Hilt, Vice President, Corporate Secretary & Associate General Counsel
Stephanie Tang, Corporate Counsel
Cheryl Brice, Assistant Secretary and Legal Specialist

Sincerely,

/s/ Denise Garner
Name: Denise Garner
Title: SVP, Chief Innovation Officer